HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the ownership structure of pharmaceutical player Corona Remedies Limited occurred on June 17, 2026, as major institutional investors stepped in to acquire a substantial stake. This massive block deal marks a key movement in the healthcare sector, involving some of the world’s most prominent asset management firms.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was headlined by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. Executed at a price of ₹1,730 per share, the transaction by Sepia alone amounted to approximately ₹748.9 crore. Adding to the sell-side momentum, Anchor Partners also divested its holdings, selling 1,61,861 shares at the same price point, worth roughly ₹28 crore.
In total, these two sellers successfully exited or reduced their positions by offloading shares worth approximately ₹776.9 crore in the pharmaceutical company, signaling a major liquidity event in the stock.
HDFC Mutual Fund Dominates the Buy Side
While the sell-side was concentrated among two entities, the buy-side saw intense participation from twelve different institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, single-handedly absorbing more than half of the total deal value. HDFC MF acquired 24,50,000 shares, an investment totaling roughly ₹423.9 crore.
Other heavyweight domestic and international players also secured significant positions:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares valued at ₹78 crore.
- Invesco Mutual Fund: Acquired 2,89,017 shares for approximately ₹50 crore.
- Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, a volume that exactly matched the quantity sold by Anchor Partners.
Global Institutional Interest in Corona Remedies
The deal also highlights growing interest from global sovereign wealth funds and specialized emerging market funds. The Abu Dhabi Investment Authority (ADIA) participated in the deal, purchasing 39,130 shares worth approximately ₹6.8 crore.
יתרה מכך, קבוצת WhiteOak הפגינה שכנוע משמעותי, כאשר קרן ה-Ashoka WhiteOak Emerging Markets Equity Fund רכשה 148,686 מניות (25.7 קרור רופי) וקרן ה-WhiteOak Capital Mutual Fund רכשה 145,000 מניות (25.1 קרור רופי). משתתפים נוספים כללו את Aberdeen Standard Sicav I, India Acorn ICAV, ו-Factory Mutual Insurance Company, מה שמדגיש את הביטחון המוסדי הרחב בחברה ברמת מחיר של 1,730 רופי.
תובנות מרכזיות
- העברת אחזקה משמעותית: Sepia Investments ו-Anchor Partners מכרו סך כולל של כ-776.9 קרור רופי ב-Corona Remedies באמצעות עסקת בלוק.
- HDFC MF כקונה המוביל: HDFC Mutual Fund היה הרוכש העיקרי, עם השקעה של 423.9 קרור רופי עבור 2.45 מיליון מניות, המהווה למעלה מ-50% משווי העסקה.
- תיאבון מוסדי רחב: העסקה ראתה השתתפות מקבוצה מגוונת של 12 משקיעים, כולל ענקיות גלובליות כמו ADIA ו-Aberdeen, לצד קרנות נאמנות הודיות מרכזיות.